Urology FDA approvals of 2016 February 13, 2017 By Urology Times Staff Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more. Risks associated with omega-3 supplementation During my preoperative visit, my surgeon handed me a list of no less then 165 medications and supplements that I should stop taking 14 days prior to my surgery. Fish and krill oil were on the list, as were aspirin and nonsteroidal anti-inflammatory drugs
(NSAIDs)—as expected. Uro Pipeline: Data from mUC combination therapy suggests efficacy, safety December 01, 2016 By Ben Schwartz Other pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism. Merck value rises after new Keytruda approval August 11, 2016 By Christine Blank Merck’s Wall Street value is climbing after its cancer drug pembrolizumab (Keytruda) received yet another approval from FDA. New agreement supports value-based pharma contracting June 01, 2016 By Tracey Walker Industry experts are using their proprietary data/analysis to help structure contracts between pharmaceutical companies and plans. Opdivo snags two new cancer approvals May 18, 2016 By Erin Bastick Nivolumab (Opdivo, Bristol-Myers Squibb) received two new approvals from FDA to treat two different cancers. New diagnostic tests help physicians predict HCV drug resistance May 12, 2016 By Tracey Walker Hep C virus testing supports value of diagnostics in precision medicine. Study: Shorter hospital stays with Xarelto March 15, 2016 By Christine Blank US hospitals using rivaroxaban (Xarelto, Janssen Pharmaceuticals) instead of warfarin (Coumadin, Bristol-Myers Squibb) to treat patients diagnosed with a venous thromboembolism (VTE) may save nearly $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days, according to a new study. FDA expands Opdivo use for metastatic melanoma February 03, 2016 By Erin Bastick FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with metastatic melanoma. FDA approves a new immune-stimulating drug to treat multiple myeloma December 02, 2015 By Erin Bastick FDA has approved elotuzumab (Empliciti, Bristol-Myers Squibb and AbbVie) for the treatment of multiple myeloma.